Mycophenolic acid, (MPA) is a non-competitive reversible inhibitor of the inosine More recently, the salt mycophenolate sodium (trade name Myfortic) has also been MPS (720 mg BID) has been shown to be therapeutically equivalent to MMF side effects in heart recipients with substantially higher...